宜明昂科-B：Achieved significant overseas licensing partnership

Investment Rating - The report on ImmuneOnco is classified as NOT RATED [2][10]. Core Insights - ImmuneOnco has successfully established an overseas licensing partnership with SynBioTx for its PD-L1xVEGF bispecific molecule IMM2510 and anti-CTLA-4 antibody IMM27M, which could yield up to US$50 million in near-term payments and over US$2.1 billion in potential milestone payments, along with royalties on global ex-China net sales [2]. - The Phase 1 clinical trial data for IMM2510 indicates promising antitumor activity, particularly in treating relapsed/refractory non-small cell lung cancer (R/R NSCLC) and thymus adeno-squamous carcinoma, with three patients achieving confirmed partial responses (PR) and seven achieving stable disease (SD) [3]. - Early pre-clinical studies of IMM27M show it has significantly stronger anti-tumor activity compared to ipilimumab, with two patients achieving confirmed PR in a Phase 1 trial for HR+ breast cancer [4]. - The company’s key asset, timdarpacept (IMM01), is advancing through clinical trials with favorable efficacy and safety profiles demonstrated in Phase 2 studies for higher risk myelodysplastic syndromes (MDS) and relapsed/refractory classical Hodgkin lymphoma (cHL) [5]. Financial Summary - For the fiscal year ending December 31, 2023, ImmuneOnco reported revenues of RMB 0 million, R&D expenses of RMB -292 million, administrative expenses of RMB -80 million, and a net loss of RMB -379 million [6]. - The year-end cash balance for 2023 was RMB 609 million [6]. Stock Data - The current market capitalization of ImmuneOnco is HK$4,714 million, with a current stock price of HK$ 12.60 [7]. - The stock has shown a 1-month performance increase of 17.7% and a 3-month increase of 6.1%, but a decline of 33.1% over the past 6 months [7].